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Abstract
Background—Annual influenza vaccination has been recommended for all persons ≥6 months 
since the 2010–11 season. New partnerships between public health agencies and medical and 
nonmedical vaccination providers have increased the number of vaccination providers and 
locations where vaccination services are delivered.
Methods—Data from the 2011–12 Behavioral Risk Factor Surveillance System (BRFSS) were 
analyzed. Point estimates of place of vaccination and 95% confidence intervals were calculated. 
Multivariable logistic regression and predictive marginal modeling were conducted to identify 
factors associated with vaccination settings.
Results—Among adults vaccinated during the 2011–12 influenza season, a doctor’s office was 
the most common place (38.4%) for receipt of influenza vaccination, with stores (e.g., 
supermarkets or drug stores) (20.1%) the next common, and workplaces (17.6%) the third 
common. Overall, reported vaccination in nonmedical settings by state ranged from 32.2% in 
California to 60.4% in Nevada, with a median of 45.8%. Characteristics significantly associated 
with an increased likelihood of receipt of vaccination in nonmedical settings were higher 
education, not having certain identified high-risk conditions, not having had a routine checkup in 
the previous 12 months, and not having a primary doctor for health care. Being a member of a 
racial/ethnic minority group, unemployed or not in the work force were significantly associated 
with a decreased likelihood of receipt of vaccination in nonmedical settings.
Conclusion—Doctor’s offices were the most common medical setting for adult influenza 
vaccination; workplaces and stores were important nonmedical settings. Increasing access to 
vaccination services in medical and nonmedical settings should be considered as important 
strategies for improving vaccination coverage. These results also can help guide development of 
strategies for achieving Healthy People 2020 objectives for influenza vaccination of adult 
populations.
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Introduction
Seasonal influenza is associated with substantial morbidity and mortality in the United 
States (1–3). Incidence of serious illness and death are higher among adults ≥65 years, 
children younger than 5 years (but especially those younger than 2 years), pregnant women, 
and persons of any age who have medical conditions that place them at increased risk for 
complications from influenza (1). The economic impact of influenza illness is substantial (1, 
2, 4, 5). Influenza vaccination is the primary tool for preventing and controlling influenza 
(1). Annual influenza vaccination has been recommended by the Advisory Committee on 
Immunization Practices (ACIP) for all persons ≥6 months since the 2010–11 season (1). By 
the 2011–12 season, influenza vaccination coverage was 38.8% for persons aged ≥18 years 
(6).
During the 2009 influenza A pdm09 (H1N1) pandemic, new partnerships between public 
health agencies and medical and nonmedical vaccination providers were formed. These 
partnerships increased the number of vaccination providers and locations where vaccination 
services are delivered (7, 8). Although a doctor’s office was the most common place for 
receipt of influenza vaccine during the 2010–11 season, vaccination in nonmedical settings, 
including stores (e.g., supermarkets or drug stores) and workplaces was also common (8). 
Nonmedical settings provide expanded convenient access to vaccinations and potentially 
lower costs for the person being vaccinated (9). Vaccination in nonmedical settings could 
both increase vaccination coverage (1) and enhance the overall capacity of the health care 
system to effectively deliver vaccinations.
To assess national and state-level influenza vaccination in medical versus nonmedical 
settings among persons ≥18 years and examine factors associated with vaccination in 
medical or nonmedical settings, data from the 2011–12 Behavioral Risk Factor Surveillance 
System (BRFSS) were analyzed.
Methods
The BRFSS is a continuous, population-based telephone survey collecting information from 
adults aged ≥18 years selected randomly using a multistage cluster design among the non-
institutionalized civilian population in 50 states and the District of Columbia (DC). The 
objective of the BRFSS is to collect uniform, state-specific data on self-reported preventive 
health practices and risk behaviors that are linked to preventable infectious diseases, chronic 
diseases, and injuries. Data are weighted by age, sex, and, in some states, race/ethnicity, to 
reflect each area’s estimated adult populations (10).
The BRFSS median Council of American Survey Research Organizations (CASRO) state 
response and cooperation rates for the 2011–12 season were 49.2% (range: 31.7%-65.1%) 
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and 73.7% (range: 49.6%-84.9%) for September-December 2011, respectively, and 47.5% 
(range: 32.1%-62.7%) and 58.9% (range: 38.1%-76.1%) for January-June 2012, respectively 
(6).
Respondents were asked whether they had received a flu vaccination during the past 12 
months and if so, in which month and year and at what type of place. Individuals who were 
interviewed September 2011 through June 2012 and reported receiving influenza vaccination 
from August 2011 through May 2012 were included in the analysis (132,743). Individuals 
for whom place of influenza vaccination data were missing (n=94, 0.07%) those who said 
they received their vaccinations in Canada or Mexico (n=53, 0.04%), those who said they 
did not know where they received their vaccination (n=224, 0.17%), and those who declined 
to answer the question (n=50, 0.04%) were excluded from the analysis. Differences in the 
reported place of vaccination were analyzed by month of interview and reported by month of 
vaccination.
Responses to the question on place of vaccination were divided into medical and nonmedical 
settings. Medical settings were doctor’s office or health maintenance organizations, health 
departments, other types of clinics or health centers (ex: a community health center), and 
hospitals (ex: inpatient) or emergency departments. Nonmedical settings were senior, 
recreation, or community centers, workplaces, stores (ex: supermarket, drug store), schools, 
and places other than those indicated here.
Covariates were selected from coded survey questions to measure associations of influenza 
vaccination with medical and nonmedical settings, including: age, sex, race/ethnicity, 
employment status, education, history of certain chronic conditions that increase the risk for 
influenza complications (i.e., asthma, diabetes, cardiovascular disease, chronic obstructive 
pulmonary disease, emphysema, chronic bronchitis, and cancer), health insurance status, 
time since last routine checkup, having a personal doctor, and cost as a barrier to seeing a 
doctor in the past 12 months.
SUDAAN (Software for the statistical analysis of correlated data, Research Triangle 
Institute, Research Triangle Park, NC) was used to calculate point estimates and 95% 
confidence intervals (CIs). T tests were used to determine significance within strata for 
medical and nonmedical settings. Statistical significance was defined as p<0.05. 
Multivariable logistic regression and predictive marginal modeling under the logistic 
procedure were conducted to calculate prevalence ratios and identify factors independently 
associated with medical and nonmedical vaccination settings.
Results
A total of 132,743 participants who were interviewed September 2011 through June 2012 
and reported receiving influenza vaccination from August 2011 through May 2012 were 
included in the analysis. Overall for the 2011–12 season, 56.9% of adults ≥18 years received 
influenza vaccination at medical settings and 43.1% at nonmedical settings. A greater 
proportion (48.8%) of younger adults 18–49 years reported vaccination at nonmedical 
settings compared with adults 50–64 years (43.2%) and ≥65 years (35.7%) (Table 1).
Lu et al. Page 3
Vaccine. Author manuscript; available in PMC 2018 February 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Overall, doctor’s office was the most common place of vaccination (38.4%), followed by 
stores (20.1%), and workplaces (17.6%) (Table 1). Doctor’s office was also the most 
common place of vaccination in each age groups: 18–49 years (30.1%), 50–64 years 
(38.2%), and ≥65 years (49.1%). For those 18–49 years and 50–64 years, workplace was the 
second most common place of influenza vaccination (28.0% and 20.3%, respectively) with 
stores the next most common (14.6% and 18.8%, respectively). For persons ≥65 years, a 
store was the second most common place of influenza vaccination (28.4%) (Table 1). There 
were no differences in reported place of vaccination by month of interview or month of 
vaccination (data not shown).
Among adults who reported influenza vaccination receipt in the 2011–12 season, the 
proportion reporting vaccination in nonmedical settings compared to the prior season was 
1.7% higher among those ≥18 years overall, 3.1% higher among those aged 18–49 years, 
and 2.7% higher among those ≥65 years (Table 1).
Overall, and in each age group, non-Hispanic whites were more likely to report vaccination 
in nonmedical settings compared with non-Hispanic blacks, Hispanics, and those reporting 
other race and ethnicity (Table 2).
Overall and across all age groups, nonmedical settings were the most likely places of 
influenza vaccination for adults who had attended college (47.0%) versus had high school 
education (39.4%) or had less than high school education (30.0%), were employed (53.5%) 
versus unemployed (32.6%) or not in the workforce (32.9%), reported no identified high-risk 
conditions (48.4%) versus had high-risk conditions (34.9%), whose last routine checkup was 
≥1 year (54.9%) versus <1 year (40.5%), or had no primary doctor (54.7%) versus had a 
primary doctor (41.9%) (Table 2). Vaccinees reporting cost was not an obstacle to medical 
care were more likely to report receiving influenza vaccination in nonmedical settings 
(43.4%) compared to vaccinees reporting cost was a barrier (40.4%) (Table 2).
Multivariable logistic regression and predictive marginal modeling were performed with 
setting of receipt of influenza vaccination as the outcome (Table 3). Overall, among adults 
≥18 years, characteristics significantly associated with an increased likelihood of receipt of 
vaccination in nonmedical settings were: higher education, not having certain identified 
high-risk conditions (i.e., asthma, diabetes, cardiovascular disease, chronic obstructive 
pulmonary disease, emphysema, chronic bronchitis, and cancer), not having had a routine 
checkup in the previous 12 months, and not having a primary doctor for health care. 
Individuals who were unemployed and not in the work force were less likely to receive 
vaccination in nonmedical settings when compared to employed individuals. Non-Hispanic 
blacks, Hispanics, and those reporting other race and ethnicity were also less likely to 
receive vaccination in a nonmedical setting compared to Non-Hispanics whites (Table 3). 
Factors independently associated with setting of receipt of influenza vaccination were 
similar across all three adult age groups (18-49 years, 50–64 years, and ≥65 years) (Table 3).
Additionally, reported vaccination in nonmedical settings ranged from 32.2% in California 
to 60.4% in Nevada, with a median of 45.8% (Table 4).
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Discussion
This study assessed national estimates of the distribution reported place of influenza 
vaccination for adults during the 2011–12 season. This study also assessed national and 
state-specific estimates of vaccination by medical and nonmedical settings and identified 
factors associated with influenza vaccination in these settings. The most common place of 
vaccination for all age groups was a doctor’s office but over 40% of adults reported 
nonmedical settings as their place for influenza vaccination. This study demonstrates both 
the continued importance of medical settings as places where adults receive influenza 
vaccination and the increasing importance of nonmedical vaccination providers. This 
information will be useful for planning and implementing strategies for achieving the 
Healthy People 2020 objectives for influenza vaccination (8, 11, 12).
Overall, 57% of adults reported influenza vaccination in medical settings, the majority in a 
doctor’s office. Older persons, those with high-risk medical conditions, those having a 
checkup in the past year, and those having a primary doctor were more likely to have been 
vaccinated in a medical setting. This might reflect increased frequency of contact with 
health-care providers because of illness, increased likelihood of provider offering, 
recommending, or reminding patients about vaccination, greater acceptance of vaccination 
by these patients, decreased access to vaccination in non-medical settings, or patient 
preference for vaccination in medical settings (8, 11). These findings might also be related to 
the age of respondents. Older adults (persons ≥50 years) were more likely to receive 
vaccination in medical settings which might reflect that they were more likely to have 
chronic conditions and as a result, were more likely to have a personal doctor or a recent 
doctor visit. To improve vaccination rates for adults, especially those with high risk 
conditions, physicians and other healthcare providers should continue recommending and 
encouraging their adult patients to receive influenza vaccination at every opportunity.
Even though the majority of adults received influenza vaccination in medical settings, a 
large proportion of influenza vaccinations took place in nonmedical settings compared to 
previous seasons. The proportion of adults vaccinated in a store (20.1%) in the 2011–12 
season increased compared to the 1998–99 (10), 2001–02 (BRFSS, CDC unpublished data), 
2004–05 (BRFSS, CDC unpublished data), and 2010–11 influenza seasons (8), when 5%, 
6%, 6%, and 18% of adults, respectively, were vaccinated in a store. Changes in state laws 
allowing more pharmacists to administer influenza vaccinations to adults and more 
pharmacies offering influenza vaccinations might have contributed to this increase (8, 13). In 
1999, only 22 states allowed pharmacists to administer influenza vaccinations to adults; by 
June 2009, all 50 states allowed pharmacists to administer influenza vaccinations to adults. 
Some states also allowed influenza vaccination of children, with the minimum age for 
people who can be vaccinated by pharmacists varying state to state (8, 13).
Overall, workplace settings were the third most common place that adults reported receiving 
influenza vaccination. The proportion of adults vaccinated in workplaces remained stable 
over the last decade, 17.9% in the 1998–99 season (11) and 17.6% in the 2011–12 season. 
The stable proportion of adults vaccinated in workplace over time may be due to other 
place(s) of vaccination increased at a higher rate over time than workplace, so the share of 
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vaccinations taking place in workplace did not change. Vaccination programs in the 
workplace could provide for more convenient access to all routine adult vaccinations in 
addition to influenza vaccine (9, 11) for working adults with and without high risk 
conditions and enhance the overall capacity of the health care system to effectively deliver 
vaccinations. Availability of influenza vaccination in the workplace is especially important 
for persons who do not regularly access the health-care system (9, 11).
Studies have shown that influenza vaccination in nonmedical settings is safe and adverse 
events are low (approximately 0.02%) (14–19). However, concern about the safety of 
influenza vaccinations administered in nonmedical settings may affect people’s attitude 
toward vaccination in these settings. Education of both medical providers and the general 
public should emphasize the safety of vaccination in nonmedical settings and encourage 
those who may not visit their usual health-care provider during the influenza vaccination 
season to seek vaccination in a convenient nonmedical setting (15–19).
Several demographic and access to care variables were significantly associated with 
vaccination setting based on multivariable analysis. Overall, non-Hispanic whites were more 
likely than non-Hispanic blacks and Hispanics to receive their vaccinations in nonmedical 
settings. Additionally, persons in all age groups who had attended college were more likely 
to receive their influenza vaccination in a nonmedical setting than those who had not 
attended college. Non-Hispanic white race/ethnicity and higher education have been 
associated with vaccination in nonmedical settings in previous studies (8, 11, 20). This 
association might result from place of vaccination preferences, differences in vaccine-
seeking behavior, or differences in availability of nonmedical settings offering vaccinations; 
workplace vaccination might not be equally available to all socioeconomic groups (8). We 
found that adults without a primary doctor and whose last doctor visit for a routine checkup 
was ≥1 year ago were more likely to be vaccinated in a nonmedical setting suggesting that 
the availability of influenza vaccination in nonmedical settings can complement health-care 
provider efforts by reaching populations less likely to be seen by providers.
Adults without high-risk conditions were more likely to receive vaccination in nonmedical 
settings. This finding might be due to adults without high-risk conditions being less likely to 
have a physician visit during the influenza season than adults with high-risk conditions. The 
universal vaccination recommendation eliminates the need to determine whether each person 
has one or more specific indications for vaccination and emphasizes the importance of 
preventing influenza among adults of all ages (1).
The proportion of adults vaccinated in nonmedical and medical settings varied widely by 
state. The wide variability in state-specific vaccination by settings might be due to the 
variability of certain vaccination delivery factors among states (e.g., medical-care delivery 
infrastructure, population norms, availability of nonmedical settings offering vaccinations, 
availability of workplace vaccination) (11, 21, 22). Allowing pharmacies to provide 
vaccinations has been shown to be associated with higher influenza vaccination coverage 
(23). One cross-sectional study showed that states that allowed pharmacists to provide 
immunizations had significantly more adults 18–64 years immunized (25.5%) than states 
without this legislation (21.6%) (p<0.01) (23). These states also had significantly more 
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adults ≥65 years immunized against influenza (68.4%) than states that did not allow 
pharmacists to give immunizations (64.7%) (p< 0.01) (23).
The findings in this study are subject to at least four limitations. First, influenza vaccination 
status and place of vaccination were based on self-reported data and were not verified by 
medical record. Second, health-care workers vaccinated in medical settings might have 
reported that they were vaccinated at the workplace; therefore, the percentage of 
vaccinations in nonmedical settings might be overestimated. Third, BRFSS data did not ask 
about reasons for participants at a particular setting, and did not collect data on distribution 
of vaccination providers by state or geography, thus we were unable to comment on whether 
where people are vaccinated is driven by personal preference versus accessibility issues.
This study demonstrates the importance of both medical and nonmedical settings for annual 
influenza and can help guide development of strategies for achieving Healthy People 2020 
objectives for influenza vaccination of adult populations. Medical settings continue to be the 
most common place of vaccination among all adults, while nonmedical settings are 
increasingly utilized for adult vaccination and should be considered as an important strategy 
for improving vaccination coverage (1). Monitoring place of vaccination can help identify 
new trends in place of influenza vaccination among adults, help shape future influenza 
immunization programs targeted at specific groups, and identify potential new partnerships. 
CDC will rotate a place of influenza vaccination question on the BRFSS core every three 
years, but states interested in monitoring place of vaccination annually can include the 
question as an optional module. Future studies regarding place of influenza vaccination 
should collect more information and try to understand why certain types of individuals 
access services in one or the other setting. Federal, state, local government, traditional and 
nontraditional vaccination providers, and community partners should collaborate to increase 
annul influenza vaccination coverage (1, 24, 25).
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Table 3
Multivariable logistic regression analysis of persons ≥ 18 years who reported receiving influenza vaccination 
in a nonmedical setting versus medical setting*, by demographic and access-to-care variables, Behavioral Risk 
Factor Surveillance System, United States, 2011–12 influenza season†
Overall 18-49 years 50-64 years 65+ years
Characteristic
Adjusted Prevalence 
Ratio
(95% CI)
Adjusted Prevalence 
Ratio
(95% CI)
Adjusted Prevalence 
Ratio
(95% CI)
Adjusted Prevalence 
Ratio
(95% CI)
Sex
 Men Referent Referent Referent Referent
 Women 1.0 (1.0-1.0) 1.0 (0.9-1.0) 1.0 (1.0-1.1) 1.0 (1.0-1.1)
Race/Ethnicity
 White, non-Hispanic Referent Referent Referent Referent
 Black, non-Hispanic 0.8 (0.7-0.8)§ 0.8 (0.8-0.9)§ 0.7 (0.6-0.8)§ 0.6 (0.5-0.7)§
 Hispanic 0.9 (0.8-0.9)§ 0.9 (0.8-1.0)§ 0.9 (0.8-1.1) 0.7 (0.6-0.9)§
 Other 0.9 (0.8-1.0)§ 1.0 (0.9-1.1) 0.8 (0.7-0.9)§ 0.7 (0.6-0.9)§
Education level
 Less than high school Referent Referent Referent Referent
 High school graduate 1.2 (1.1-1.3)§ 1.1 (1.0-1.3) 1.2 (1.0-1.4)§ 1.2 (1.0-1.3)§
 Attended college 1.2 (1.2-1.3)§ 1.3 (1.1-1.5)§ 1.3 (1.1-1.5)§ 1.2 (1.1-1.4)§
Employment status
 Employed Referent Referent Referent Referent
 Unemployed 0.6 (0.6-0.7)§ 0.6 (0.5-0.7)§ 0.7 (0.6-0.8)§ 0.7 (0.5-0.8)§
 Not in work force 0.7 (0.7-0.7)§ 0.6 (0.5-0.7)§ 0.7 (0.6-0.7)§ 0.8 (0.8-0.9)§
Certain chronic conditions
 Yes Referent Referent Referent Referent
 No 1.2 (1.1-1.2)§ 1.1 (1.1-1.2)§ 1.3 (1.2-1.3)§ 1.2 (1.1-1.2)§
Time since last routine checkup
 <1 yr Referent Referent Referent Referent
 ≥1 yrs 1.2 (1.2-1.3)§ 1.1 (1.1-1.2)§ 1.3 (1.2-1.4)§ 1.3 (1.2-1.4)§
Health insurance coverage
 Yes Referent Referent Referent Referent
 No 1.0 (0.9-1.1) 1.0 (0.9-1.1) 1.1 (0.9-1.2) 1.0 (0.8-1.2)
Personal doctor
 Yes Referent Referent Referent Referent
 No 1.2 (1.1-1.2)§ 1.2 (1.1-1.2)§ 1.1 (1.0-1.3)§ 1.3 (1.1-1.4)§
Cost an obstacle to medical care
 Yes Referent Referent Referent Referent
 No 1.0 (1.0-1.1) 1.0 (0.9-1.1) 1.1 (1.0-1.2) 1.0 (0.9-1.1)
Abbreviations: CI=confidence interval.
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*Workplace, store, senior/recreation/community center, school, or other.
†
Individuals reported receiving influenza vaccination during August 2011 through May 2012.
§p<0.05 by t test for comparisons within each variable with the indicated reference level.
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Table 4
Place of seasonal influenza vaccination of adults aged ≥18 years by state, Behavioral Risk Factor Surveillance 
System, United States, 2011–12 influenza season*
Medical setting† Nonmedical setting§
N % (95% CI) N % (95% CI)
Nevada 468 39.6 (35.2-44.2) 661 60.4 (55.8-64.8)
Arizona 902 47.4 (43.4-51.5) 1,003 52.6 (48.5-56.6)
Nebraska 4,450 47.6 (46.0-49.3) 3,719 52.4 (50.7-54.0)
Illinois 800 48.2 (44.2-52.1) 783 51.8 (47.9-55.8)
Oregon 781 48.7 (45.6-51.7) 776 51.3 (48.3-54.4)
Rhode Island 917 49.2 (46.2-52.2) 984 50.8 (47.8-53.8)
Texas 1,341 49.4 (46.3-52.5) 1,397 50.6 (47.5-53.7)
South Dakota 931 49.8 (45.3-54.2) 794 50.2 (45.8-54.7)
Indiana 1,050 49.8 (46.9-52.7) 941 50.2 (47.3-53.1)
Utah 1,482 50.0 (47.5-52.5) 1,337 50.0 (47.5-52.5)
Connecticut 1,230 50.5 (47.5-53.5) 1,127 49.5 (46.5-52.5)
South Carolina 1,920 51.3 (48.6-53.9) 1,551 48.7 (46.1-51.4)
Colorado 1,921 51.6 (49.0-54.2) 1,849 48.4 (45.8-51.0)
Arkansas 733 52.5 (48.4-56.6) 595 47.5 (43.4-51.6)
Iowa 1,331 52.8 (50.3-55.3) 1,117 47.2 (44.7-49.7)
Florida 995 52.9 (48.9-56.8) 758 47.1 (43.2-51.1)
Virginia 884 52.9 (49.2-56.6) 808 47.1 (43.4-50.8)
District of Columbia 690 53.2 (48.8-57.5) 576 46.8 (42.5-51.2)
Montana 1,248 53.3 (50.2-56.4) 1,082 46.7 (43.6-49.8)
Oklahoma 1,330 53.6 (50.8-56.3) 1,013 46.4 (43.7-49.2)
Kansas 3,005 53.9 (52.2-55.7) 2,380 46.1 (44.3-47.8)
Missouri 894 54.0 (50.6-57.5) 663 46.0 (42.5-49.4)
Washington 2,563 54.0 (51.7-56.3) 2,160 46.0 (43.7-48.3)
Delaware 857 54.1 (50.8-57.5) 716 45.9 (42.5-49.2)
Maryland 2,056 54.2 (51.1-57.4) 1,579 45.8 (42.6-48.9)
Ohio 1,615 54.2 (51.6-56.7) 1,293 45.8 (43.3-48.4)
Alaska 419 54.4 (49.2-59.5) 308 45.6 (40.5-50.8)
Idaho 797 54.6 (49.8-59.3) 654 45.4 (40.7-50.2)
North Carolina 2,377 55.3 (53.1-57.5) 1,809 44.7 (42.5-46.9)
Kentucky 2,040 55.5 (53.0-58.0) 1,388 44.5 (42.0-47.0)
Wyoming 886 55.7 (51.9-59.4) 779 44.3 (40.6-48.1)
Tennessee 1,195 55.8 (49.7-61.8) 835 44.2 (38.2-50.3)
Georgia 1,080 56.1 (52.7-59.4) 721 43.9 (40.6-47.3)
Wisconsin 654 56.4 (51.7-61.0) 449 43.6 (39.0-48.3)
Minnesota 2,897 57.0 (55.0-59.1) 2,214 43.0 (40.9-45.0)
Mississippi 1,311 57.6 (54.6-60.6) 743 42.4 (39.4-45.4)
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Medical setting† Nonmedical setting§
N % (95% CI) N % (95% CI)
Maine 1,935 57.8 (55.5-60.1) 1,293 42.2 (39.9-44.5)
New Jersey 1,968 57.9 (55.3-60.5) 1,339 42.1 (39.5-44.7)
New Hampshire 1,182 58.3 (55.4-61.2) 764 41.7 (38.8-44.6)
North Dakota 867 58.9 (55.6-62.2) 566 41.1 (37.8-44.4)
New Mexico 1,401 59.6 (57.0-62.2) 983 40.4 (37.8-43.0)
Alabama 1,534 59.7 (56.8-62.5) 887 40.3 (37.5-43.2)
West Virginia 1,105 60.0 (57.2-62.8) 659 40.0 (37.2-42.8)
Massachusetts 4,209 60.4 (58.4-62.3) 2,707 39.6 (37.7-41.6)
Vermont 1,311 61.4 (58.5-64.2) 727 38.6 (35.8-41.5)
Louisiana 1,561 62.1 (58.8-65.4) 832 37.9 (34.6-41.2)
Michigan 1,712 62.4 (59.0-65.8) 958 37.6 (34.2-41.0)
Pennsylvania 3,089 63.0 (60.9-65.1) 1,673 37.0 (34.9-39.1)
Hawaii 1,192 64.8 (61.3-68.2) 636 35.2 (31.8-38.7)
New York 1,113 66.9 (63.8-69.8) 565 33.1 (30.2-36.2)
California 1,602 67.8 (65.1-70.5) 761 32.2 (29.5-34.9)
median 54.2 45.8
range 39.6-67.8 32.2-60.4
Abbreviations: CI=confidence interval
*
Individuals reported receiving influenza vaccination during August 2011 through May 2012
†
Doctor’s office/health maintenance organization, health department, another type of clinic/health center, or hospital/emergency department
§Workplace, store, senior/recreation/community center, school, or other
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